BIOMARIN PHARMACEUTICAL INC Net Income (Loss) Attributable to Parent in USD from Q1 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Biomarin Pharmaceutical Inc quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2010 to Q3 2025.
  • Biomarin Pharmaceutical Inc Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2025 was -$30.7M, a 129% decline year-over-year.
  • Biomarin Pharmaceutical Inc Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2025 was $520M, a 61.5% increase year-over-year.
  • Biomarin Pharmaceutical Inc annual Net Income (Loss) Attributable to Parent for 2024 was $427M, a 155% increase from 2023.
  • Biomarin Pharmaceutical Inc annual Net Income (Loss) Attributable to Parent for 2023 was $168M, a 18.4% increase from 2022.
  • Biomarin Pharmaceutical Inc annual Net Income (Loss) Attributable to Parent for 2022 was $142M.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)

BIOMARIN PHARMACEUTICAL INC Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $520M -$30.7M -$137M -129% Jul 1, 2025 Sep 30, 2025 10-Q 2025-10-28
Q2 2025 $657M $241M +$133M +124% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-05
Q1 2025 $524M $186M +$97M +109% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-02
Q4 2024 $427M $125M +$105M +513% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-24
Q3 2024 $322M $106M +$65.7M +163% Jul 1, 2024 Sep 30, 2024 10-Q 2025-10-28
Q2 2024 $257M $107M +$51.1M +91.2% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-05
Q1 2024 $205M $88.7M +$37.8M +74.4% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-02
Q4 2023 $168M $20.4M +$20.6M Oct 1, 2023 Dec 31, 2023 10-K 2025-02-24
Q3 2023 $147M $40.4M +$47M Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-31
Q2 2023 $100M $56M +$28.4M +103% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-05
Q1 2023 $71.6M $50.9M -$69.9M -57.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-04-26
Q4 2022 $142M -$249K +$57.6M +99.6% Oct 1, 2022 Dec 31, 2022 10-K 2025-02-24
Q3 2022 $83.9M -$6.65M +$29.8M +81.8% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 $54.1M $27.7M +$14.7M +114% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 $39.3M $121M +$103M +595% Jan 1, 2022 Mar 31, 2022 10-Q 2023-04-28
Q4 2021 -$64.1M -$57.9M -$74.9M -440% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-26
Q3 2021 $10.8M -$36.5M -$821M -105% Jul 1, 2021 Sep 30, 2021 10-Q 2022-10-28
Q2 2021 $832M $12.9M +$42.1M Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $790M $17.4M -$64M -78.7% Jan 1, 2021 Mar 31, 2021 10-Q 2022-04-29
Q4 2020 $854M $17M +$2M +13.3% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-27
Q3 2020 $852M $785M +$730M +1326% Jul 1, 2020 Sep 30, 2020 10-Q 2021-10-29
Q2 2020 $122M -$29.2M +$8.25M +22% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-30
Q1 2020 $114M $81.4M +$138M Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-30
Q4 2019 -$23.8M $15M +$18.7M Oct 1, 2019 Dec 31, 2019 10-K 2022-02-25
Q3 2019 -$42.5M $55M +$67.7M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-06
Q2 2019 -$110M -$37.4M -$20.6M -123% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 -$89.5M -$56.5M -$12.3M -27.9% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-01
Q4 2018 -$77.2M -$3.65M +$47.7M +92.9% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-26
Q3 2018 -$125M -$12.6M -$93K -0.74% Jul 1, 2018 Sep 30, 2018 10-Q/A 2019-11-04
Q2 2018 -$125M -$16.8M +$20M +54.4% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-02
Q1 2018 -$145M -$44.1M -$27.9M -171% Jan 1, 2018 Mar 31, 2018 10-Q 2019-04-29
Q4 2017 -$117M -$51.4M +$39.3M +43.4% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-27
Q3 2017 -$156M -$12.5M +$24.9M +66.5% Jul 1, 2017 Sep 30, 2017 10-Q 2018-10-26
Q2 2017 -$181M -$36.8M +$382M +91.2% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-03
Q1 2017 -$563M -$16.3M +$66.8M +80.4% Jan 1, 2017 Mar 31, 2017 10-Q 2018-04-27
Q4 2016 -$630M -$90.7M -$159M -232% Oct 1, 2016 Dec 31, 2016 10-K 2019-02-28
Q3 2016 -$471M -$37.4M +$53.5M +58.8% Jul 1, 2016 Sep 30, 2016 10-Q 2017-10-31
Q2 2016 -$524M -$419M -$337M -411% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-02
Q1 2016 -$187M -$83.1M -$15.6M -23% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-04
Q4 2015 -$172M $68.6M +$138M Oct 1, 2015 Dec 31, 2015 10-K 2018-02-26
Q3 2015 -$310M -$90.9M -$98.4M -1321% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-03
Q2 2015 -$212M -$82M -$48.5M -145% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-08
Q1 2015 -$163M -$67.5M -$29.4M -77.1% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-02
Q4 2014 -$134M -$69.8M -$7.81M -12.6% Oct 1, 2014 Dec 31, 2014 10-K 2017-02-27
Q3 2014 -$126M $7.45M +$60.5M Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-02
Q2 2014 -$187M -$33.5M -$12M -55.6% Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-05
Q1 2014 -$175M -$38.1M +$1.7M +4.26% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-05
Q4 2013 -$176M -$62M -$8.98M -16.9% Oct 1, 2013 Dec 31, 2013 10-K 2016-02-29
Q3 2013 -$167M -$53M -$47.7M -890% Jul 1, 2013 Sep 30, 2013 10-Q 2014-10-28
Q2 2013 -$120M -$21.5M +$10.5M +32.7% Apr 1, 2013 Jun 30, 2013 10-Q 2014-07-31
Q1 2013 -$130M -$39.8M -$15.8M -66.1% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-02
Q4 2012 -$114M -$53M -$26.3M -98.3% Oct 1, 2012 Dec 31, 2012 10-K 2015-03-02
Q3 2012 -$88.1M -$5.36M +$12.3M +69.7% Jul 1, 2012 Sep 30, 2012 10-Q 2013-10-28
Q2 2012 -$100M -$32M -$26.9M -530% Apr 1, 2012 Jun 30, 2012 10-Q 2013-07-29
Q1 2012 -$73.4M -$24M -$19.6M -448% Jan 1, 2012 Mar 31, 2012 10-Q 2013-04-29
Q4 2011 -$53.8M -$26.7M -$14.5M -119% Oct 1, 2011 Dec 31, 2011 10-K 2014-02-26
Q3 2011 -$39.3M -$17.7M -$235M -108% Jul 1, 2011 Sep 30, 2011 10-Q 2012-10-29
Q2 2011 $196M -$5.08M -$4.6M -964% Apr 1, 2011 Jun 30, 2011 10-Q 2012-08-02
Q1 2011 $200M -$4.37M -$5.52M -480% Jan 1, 2011 Mar 31, 2011 10-Q 2012-04-30
Q4 2010 $206M -$12.2M Oct 1, 2010 Dec 31, 2010 10-K 2013-02-26
Q3 2010 $217M Jul 1, 2010 Sep 30, 2010 10-Q 2011-10-31
Q2 2010 -$477K Apr 1, 2010 Jun 30, 2010 10-Q 2011-08-01
Q1 2010 $1.15M Jan 1, 2010 Mar 31, 2010 10-Q 2011-04-29

BIOMARIN PHARMACEUTICAL INC Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $427M +$259M +155% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-24
2023 $168M +$26.1M +18.4% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-24
2022 $142M +$206M Jan 1, 2022 Dec 31, 2022 10-K 2025-02-24
2021 -$64.1M -$918M -108% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-26
2020 $854M +$878M Jan 1, 2020 Dec 31, 2020 10-K 2023-02-27
2019 -$23.8M +$53.4M +69.1% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-25
2018 -$77.2M +$39.8M +34% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-26
2017 -$117M +$513M +81.4% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-27
2016 -$630M -$458M -267% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-28
2015 -$172M -$37.8M -28.2% Jan 1, 2015 Dec 31, 2015 10-K 2018-02-26
2014 -$134M +$42.4M +24% Jan 1, 2014 Dec 31, 2014 10-K 2017-02-27
2013 -$176M -$62M -54.2% Jan 1, 2013 Dec 31, 2013 10-K 2016-02-29
2012 -$114M -$60.5M -112% Jan 1, 2012 Dec 31, 2012 10-K 2015-03-02
2011 -$53.8M -$260M -126% Jan 1, 2011 Dec 31, 2011 10-K 2014-02-26
2010 $206M Jan 1, 2010 Dec 31, 2010 10-K 2013-02-26
* An asterisk sign (*) next to the value indicates that the value is likely invalid.